510(k) K242256

QIAstat-Dx Meningitis/Encephalitis (ME) Panel by QIAGEN GmbH — Product Code PLO

K242256 is an FDA 510(k) premarket notification submitted by QIAGEN GmbH for the device "QIAstat-Dx Meningitis/Encephalitis (ME) Panel". The FDA issued a decision of Substantially Equivalent on October 29, 2024. The device falls under product code PLO (Meningitis/Encephalitis Pathogen Multiplex Nucleic Acid Detection System), a Class II device regulated under 21 CFR 866.3970. QIAGEN GmbH has at least 10 other 510(k) clearances on record.

Clearance Details

Decision
SESE (Substantially Equivalent)
Decision Date
October 29, 2024
Date Received
July 31, 2024
Clearance Type
Traditional
Expedited Review
No
Third Party Review
No

Device Classification

Device Name
Meningitis/Encephalitis Pathogen Multiplex Nucleic Acid Detection System
Device Class
Class II
Regulation Number
866.3970
Review Panel
MI
Submission Type

A meningitis/encephalitis pathogen multiplex nucleic acid detection system is a qualitative in vitro diagnostic test for the direct detection and identification of microbial-associated nucleic acids in cerebrospinal fluid. The test is indicated for individuals with signs and symptoms of meningitis or encephalitis and aids in diagnosis of agents of meningitis or encephalitis when used in conjunction with clinical and other laboratory findings.